Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 07, 2019 06:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients...
January 07, 2019 06:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients...
December 02, 2018 12:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 246

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of...
December 02, 2018 12:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 246

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of...
November 30, 2018 07:50 ET | Source: Karolinska Development AB (publ)

SEK 512 miljoner finansiering genomförd i Karolinska Developments portföljbolag Aprea Therapeutics

STOCKHOLM, 30 november 2018. Karolinska Development (Nasdaq Stockholm: KDEV) meddelar att ett investerarkonsortium med bland andra amerikanska Redmile Group investerar SEK 512 miljoner (EUR 50...
November 30, 2018 07:50 ET | Source: Karolinska Development AB (publ)

Financing of SEK 512 million secured in Karolinska Development's portfolio company Aprea Therapeutics

STOCKHOLM, 30 November 2018. Karolinska Development (Nasdaq Stockholm: KDEV) announces that an investment consortium, including Redmile Group, invests SEK 512 million (EUR 50 million) in Aprea...
November 13, 2018 02:00 ET | Source: Karolinska Development AB (publ)

Delårsrapport för januari - september 2018

STOCKHOLM - den 13 november 2018. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari - september 2018. Den fulla rapporten är tillgänglig på bolagets...
November 13, 2018 02:00 ET | Source: Karolinska Development AB (publ)

Interim Report January - September 2018

STOCKHOLM - 13 November 2018. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report for the period January - September 2018. The full report is available on the...
November 07, 2018 02:30 ET | Source: Karolinska Development AB (publ)

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's...
November 07, 2018 02:30 ET | Source: Karolinska Development AB (publ)

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's...